Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000874643 | SCV001016840 | benign | Adrenoleukodystrophy | 2024-01-30 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001000377 | SCV001157136 | benign | not specified | 2018-12-19 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001552172 | SCV001772819 | likely benign | not provided | 2021-06-29 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000874643 | SCV002045861 | benign | Adrenoleukodystrophy | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002372483 | SCV002683501 | benign | Inborn genetic diseases | 2018-01-30 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV003930416 | SCV004740882 | likely benign | ABCD1-related disorder | 2019-08-01 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Natera, |
RCV000874643 | SCV001466686 | likely benign | Adrenoleukodystrophy | 2020-08-12 | no assertion criteria provided | clinical testing |